Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Mechanical Structure Complications After Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Intervention:   Diagnostic Test: Heart rupture
Sponsor:   Xiamen Cardiovascular Hospital, Xiamen University
Recruiting

Internat-based Treatment of Stress and Anxiety in Myocardial Infarction With Non-obstructive Coronary Arteries

Condition:   Myocardial Infarction
Intervention:   Behavioral: Internet-based CBT intervention
Sponsors:   Per Tornvall;   UPPSALA UNIVERSITET;   Mid Sweden University
Not yet recruiting

A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

Conditions:   Heart Attack;   NSTEMI
Interventions:   Biological: AMI MultiStem cells;   Other: Sham
Sponsors:   Athersys, Inc;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting

Comparison of Radial and Ulnar Artery Intervention in Patients With ST Elevated Myocardial Infarction

Condition:   ST Elevated Myocardial Infarction
Intervention:   Procedure: primary percutaneous coronary intervention
Sponsors:   Sakarya University;   Cosansu, Kahraman, M.D.
Recruiting

High-Intensity Interval Training Early After Left Ventricular Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Other: HIIT;   Other: MICE
Sponsor:   University Hospital Inselspital, Berne
Recruiting

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Empagliflozin 10 mg;   Drug: Placebo Oral Tablet
Sponsors:   Medical University of Graz;   United Arab Emirates University;   Medical University of Vienna;   Landeskrankenhaus Feldkirch;   Paracelsus Medical University;   Hospital Rudolfstiftung;   Klinikum Klagenfurt am Wörthersee;   Barmherzige Brüder Eisenstadt;   Kardinal Schwarzenberg Klinikum Schwarzach St. Veit;   Johannes Kepler University of Linz;   Landesklinikum Sankt Polten;   Landeskrankenhaus II Graz West
Recruiting

Myocardial Infarction With Non-Obstructive Coronary Arteries in the Greek Population

Conditions:   Acute Myocardial Infarction;   Non-Obstructive Coronary Atherosclerosis;   Ischemic Heart Disease;   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Other: MINOCA registry;   Diagnostic Test: CCTA Phenotypes
Sponsor:   AHEPA University Hospital
Not yet recruiting

BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction

Conditions:   Myocardial Infarction;   Myocardial Infarction, Acute;   Myocardial Infarction Old
Intervention:   Device: BioMonitor
Sponsor:   Biotronik SE & Co. KG
Recruiting

Physical Activity Intervention in ELderly Patients With Myocardial INfarction

Conditions:   Myocardial Infarction;   Aging
Interventions:   Other: Health Education;   Other: Exercise Intervention
Sponsors:   University Hospital of Ferrara;   Azienda Usl di Bologna
Not yet recruiting

Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock

Conditions:   Acute Myocardial Infarction;   Cardiogenic Shock
Intervention:   Device: VA-ECMO
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting

The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial

Condition:   Anterior Wall Myocardial Infarction
Interventions:   Biological: Plasma-Lyte A and 25% Autologous Plasma;   Biological: Autologous EPCs;   Biological: Autologous EPCs Transfected with human eNOS
Sponsors:   Ottawa Hospital Research Institute;   Canadian Institutes of Health Research (CIHR);   Stem Cell Network
Active, not recruiting

WAMIF : Young Women Presenting Acute Myocardial Infarction in France

Conditions:   Acute Myocardial Infarction;   Women Over 18 and Under 50 Years of Age
Intervention:   Other: Specific blood sample of women under 50 years with acute MI
Sponsors:   French Cardiology Society;   French Federation of Cardiology;   I.V.S. Institut des Vaisseaux et du Sang;   Biosensors Europe SA;   AstraZeneca;   Boston Scientific Corporation;   Abbott Medical Devices;   Terumo Corporation;   Daiichi Sankyo, Inc.;   Hexacath, France;   Biotronik SE & Co. KG
Recruiting

Effects of Dried Bilberry, Liquid Oats, or Their Combination After AMI

Condition:   Myocardial Infarction
Interventions:   Dietary Supplement: Bilberry;   Dietary Supplement: Placebo;   Dietary Supplement: Liquid oats;   Dietary Supplement: Combination bilberry/oats
Sponsors:   Ole Frobert, MD, PhD;   Region Västmanland;   Region Skane;   Chalmers University of Technology;   Västerbotten County Council
Not yet recruiting

Comparison of Two Exercise Training Modes on Left Myocardial Regional Function After Myocardial Infarction Evaluated by 2D Strain Ultrasound

Condition:   Ischemic Cardiomyopathy
Intervention:   Other: Intermittent retraining program.
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Not yet recruiting

Is the 4MGS a Useful Outcome Measure Post-PPCI

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsors:   Royal Brompton & Harefield NHS Foundation Trust;   Medical Research Council
Active, not recruiting

Medical-economic Evaluation Comparing Intensive Outpatient Monitoring of Neuro-cardiovascular Diseases by Nurses, Doctors and Hospital and Private-sector Pharmacists, Compared to Usual Monitoring.

Conditions:   Cerebrovascular Accidents;   Myocardial Infarction
Interventions:   Other: Usual follow-up;   Other: Intensive follow-up
Sponsor:   Centre Hospitalier Universitaire Dijon
Not yet recruiting

Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium

Conditions:   Coronary Artery Disease;   ST-segment Elevation Myocardial Infarction
Intervention:   Drug: Iodixanol
Sponsor:   GE Healthcare
Recruiting

Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue

Condition:   Myocardial Infarction
Interventions:   Combination Product: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.;   Procedure: Surgery by sternotomy
Sponsors:   Fundació Institut Germans Trias i Pujol;   Germans Trias i Pujol Hospital
Recruiting

Technical Development of Cardiovascular Magnetic Resonance Imaging

Conditions:   Cardiomyopathy;   Congenital Heart Disease;   Cardiovascular Disease;   Cardiac Magnetic Resonance Imaging;   Acute Myocardial Infarction
Intervention:   Device: Siemens MRI scanner
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Suspended

Bivalirudin in Late PCI for Oatients With STEMI

Condition:   STEMI - ST Elevation Myocardial Infarction
Interventions:   Drug: Bivalirudin;   Drug: Heparin
Sponsor:   Second Xiangya Hospital of Central South University
Not yet recruiting

Mechanisms of Action of Acetaminophen

Conditions:   Myocardial Infarction;   Arthritis
Interventions:   Drug: Aspirin First;   Drug: Aspirin Last;   Drug: Acetaminophen 1000 mg/d;   Drug: Acetaminophen 4000 mg/d;   Drug: Ibuprofen 800 mg/d
Sponsor:   University of Pennsylvania
Completed

ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow

Conditions:   Heart Attack;   Stroke;   Cardiovascular Death
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Brilinta Clinical Experience Investigation

Condition:   Acute Coronary Syndrome, Old Myocardial Infarction
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Mental Stress and Myocardial Ischemia After MI: Sex Differences, Mechanisms and Prognosis

Condition:   Myocardial Infarction
Intervention:   Other: Stress Challenge
Sponsors:   Emory University;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

Condition:   Atherosclerotic Cardiovascular Disease
Interventions:   Drug: Inclisiran;   Drug: Placebo
Sponsors:   University of Oxford;   The Medicines Company;   The TIMI Study Group
Recruiting

Use of CGM for Diabetes Management Following a Hospitalization.

Condition:   Diabetes
Intervention:   Device: Continuous Glucose Monitor
Sponsor:   University of Virginia
Withdrawn

Clinical Presentations Before AMI Onset and Coronary Atherosclerosis

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Harbin Medical University
Completed

The TransCatheter Valve and Vessels Trial

Conditions:   Aortic Stenosis;   Multi Vessel Coronary Artery Disease;   TAVI;   CABG;   PCI;   Fractional Flow Reserve
Interventions:   Device: FFR-guided PCI and TAVI;   Device: CABG and SAVR
Sponsors:   Maatschap Cardiologie Zwolle;   Medtronic
Recruiting

PremiCron Suture for Cardiac Valve Repair

Condition:   Aortic Valve Stenosis
Intervention:  
Sponsors:   Aesculap AG;   B.Braun Surgical SA
Recruiting

COcoa Supplement and Multivitamin Outcomes Study

Conditions:   Cardiovascular Disease;   Cancer
Interventions:   Dietary Supplement: Cocoa extract;   Dietary Supplement: Multivitamin;   Dietary Supplement: Cocoa extract placebo;   Dietary Supplement: Multivitamin placebo
Sponsors:   Brigham and Women's Hospital;   Fred Hutchinson Cancer Research Center;   Mars, Inc.;   Pfizer;   Columbia University
Active, not recruiting

PPI's and SSRI's Therapy for the Management of NCCP

Condition:   Chest Pain Rule Out Myocardial Infarction
Intervention:   Drug: Citalopram
Sponsor:   Evangelismos Hospital
Terminated

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Conditions:   Hypertension;   Diabetes;   Death From Cardiovascular Disease;   Myocardial Infarction;   Stroke
Intervention:  
Sponsors:   Imperial College London;   Pfizer
Completed

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Diseases
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Active, not recruiting

Comparison of the Severity of Coronary Atherosclerosis With Tissue Compliance in Patients Within First Degree Relatives

Condition:   Coronary Artery Disease With Myocardial Infarction
Intervention:   Diagnostic Test: there is not any intervention procedure
Sponsor:   TC Erciyes University
Not yet recruiting

Prospective Multicenter Study for Early Evaluation of Acute Chest Pain

Conditions:   Chest Pain;   Acute Aortic Dissection;   Pulmonary Embolism;   Acute Myocardial Infarction Type 1;   Acute Coronary Syndrome
Interventions:   Diagnostic Test: Coronary angiography;   Diagnostic Test: CT angiography of aorta;   Diagnostic Test: CT angiography of pulmonary arteries.;   Diagnostic Test: Electrocardiogram;   Diagnostic Test: Cardiac Troponin
Sponsor:   West China Hospital
Recruiting

Genetic Factors in Atherosclerosis

Condition:   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
Sponsor:   CSL Behring
Recruiting

Diuretic Comparison Project

Condition:   Hypertension
Interventions:   Drug: Hydrochlorothiazide (HCTZ);   Drug: Chlorthalidone
Sponsor:   VA Office of Research and Development
Recruiting

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance to Examine the Safety of Cessation of Dual Anti-Platelet Therapy in High Bleeding Risk Patients at One Month

Conditions:   Coronary Artery Disease;   Atherosclerosis;   Stent Placement
Interventions:   Drug: Dual Antiplatelet (DAPT) Therapy;   Device: The Synergy® stent
Sponsors:   HonorHealth Research Institute;   Boston Scientific Corporation
Recruiting

Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study

Conditions:   Ischemic Heart Disease;   Coronary Artery Disease
Intervention:   Device: XIENCE Sierra
Sponsor:   Fundación EPIC
Active, not recruiting

Machine Learning in Quantitative Stress Echocardiography

Conditions:   Cardiovascular Diseases;   Ischaemic Heart Disease
Intervention:   Other: Analysis
Sponsors:   Hull University Teaching Hospitals NHS Trust;   Barts & The London NHS Trust;   Cardiff and Vale University Health Board
Recruiting

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Conditions:   Overweight;   Obesity
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Active, not recruiting

Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

Conditions:   Acute Coronary Syndrome;   Chest Pain
Interventions:   Procedure: Cardiac MRI;   Other: ACC/AHA Guideline adherent care
Sponsors:   Wake Forest University Health Sciences;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Condition:   Type 2 Diabetes
Interventions:   Drug: SGLT2 inhibitor;   Drug: GLP-1 receptor agonist
Sponsor:   University of Padova
Completed

Hepatitis C Treatment and Atherosclerosis

Conditions:   Chronic Hepatitis C;   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Ticagrelor;   Drug: Rivaroxaban
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting

Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia

Condition:   Critical Limb Ischemia
Interventions:   Drug: rivaroxaban plus aspirin;   Drug: clopidogrel plus aspirin
Sponsors:   Ottawa Hospital Research Institute;   The Ottawa Hospital
Completed

Cohort Study - SBRT for VT Radioablation

Conditions:   Ventricular Tachycardia;   Myocardial Infarction;   Heart Disease Structural Disorder
Intervention:   Radiation: Stereotactic Body Radiotherapy (SBRT) ablation of VT
Sponsor:   John Sapp
Not yet recruiting

Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

Condition:   End-Stage Kidney Disease
Interventions:   Other: Default dialysate sodium concentration of 137mmol/l;   Other: Default dialysate sodium concentration of 140mmol/l
Sponsors:   The George Institute;   Australasian Kidney Trials Network
Recruiting

Diuretics and Volume Overload in Early CKD

Condition:   Chronic Kidney Disease
Intervention:   Drug: Diuretic initiation or augmentation
Sponsor:   VA Office of Research and Development
Not yet recruiting

XIENCE 28 USA Study

Conditions:   Bleeding Disorder;   Ischemic Stroke;   Hemorrhagic Stroke;   Hematological Diseases;   Thrombocytopenia;   Coagulation Disorder;   Anemia;   Renal Insufficiency;   Coronary Artery Disease
Interventions:   Device: XIENCE;   Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)
Sponsor:   Abbott Medical Devices
Recruiting

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

Conditions:   Acute Coronary Syndrome;   Angina, Unstable
Interventions:   Drug: Ticagrelor;   Drug: Eptifibatide;   Drug: Clopidogrel
Sponsor:   University of Alabama at Birmingham
Completed

Endothelial Effects of VEGF Inhibition In Vivo in Man

Condition:   Cardiovascular Diseases
Intervention:  
Sponsors:   NHS Greater Glasgow and Clyde;   University of Glasgow
Completed

Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients

Condition:   Hyperuricemia
Interventions:   Drug: Febuxostat;   Drug: Placebo
Sponsor:   Sun Yat-sen University
Recruiting

Insulin Resistance and Atherosclerosis in Women With Lupus

Conditions:   Systemic Lupus Erythematosus;   Insulin Resistance;   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.;   Gilead Sciences
Active, not recruiting

Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine

Conditions:   Cardiovascular Diseases;   Atherosclerosis;   Inflammation;   Diabetes
Interventions:   Drug: Colchicine Oral Product;   Drug: Placebo oral capsule
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research (CIHR)
Not yet recruiting

Effect of Diet on Vascular Disease in Pre-Menopausal Women

Conditions:   Cardiovascular Diseases;   Vascular Disease;   Inflammation;   Insulin;   Triglycerides
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Sponsor:   Medtronic Vascular
Active, not recruiting

Diagnosis of Pheochromocytoma

Conditions:   Pheochromocytoma;   Endocrine Disease;   Endocrine Diseases
Interventions:   Drug: Fluorodopamine;   Drug: F-18 Fluorodopa
Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting

RESOLUTE ONYX Post-Approval Study

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Sponsor:   Medtronic Vascular
Active, not recruiting

Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy

Condition:   Ischemic Cardiomyopathy
Interventions:   Biological: WJMSCs Vs. placebo;   Biological: Placebo
Sponsors:   Navy General Hospital, Beijing;   First People's Hospital of Foshan;   General Hospital of Armed Police, Beijing;   PLA General Hospital, Beijing
Not yet recruiting

Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR

Conditions:   Coronary Artery Disease;   Left Main Coronary Artery Stenosis;   Left Main Coronary Artery Disease;   Restenosis, Coronary
Intervention:   Other: Indication of revascularization
Sponsor:   Fundación EPIC
Recruiting

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
Sponsor:   GlaxoSmithKline
Recruiting

PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis

Conditions:   Psoriatic Arthritis;   Atherosclerosis
Interventions:   Drug: Rosuvastatin;   Other: Treat-to-target strategy
Sponsor:   Chinese University of Hong Kong
Not yet recruiting

The FAVOR III China Study

Conditions:   Coronary Artery Disease;   Myocardial Ischaemia;   Coronary Circulation;   Coronary Stenosis;   Percutaneous Coronary Intervention
Interventions:   Diagnostic Test: QFR;   Diagnostic Test: Angiography
Sponsor:   China National Center for Cardiovascular Diseases
Recruiting

Optimal Hemostasis Duration for Percutaneous Coronary Intervention Via Snuffbox Approach

Conditions:   Bleeding;   Artery Injury
Intervention:   Procedure: Percutaneous coronary intervention via snuffbox approach
Sponsors:   Chonnam National University Hospital;   Wakayama Medical University;   The Catholic University of Korea
Recruiting

A Prospective Study on the Safety and Efficacy of Apixaban for the PReventiOn of ThromboEmbolism in Adults With Congenital HearΤ Disease and Atrial ARrhythmias

Conditions:   Congenital Heart Disease;   Atrial Arrhythmia;   Thromboembolism;   Anticoagulants Causing Adverse Effects in Therapeutic Use
Intervention:   Drug: Apixaban
Sponsors:   AHEPA University Hospital;   Onassis Cardiac Surgery Centre;   Attikon Hospital;   MITERA Children's Hospital
Recruiting

Peer Mentored Approaches For Men And Women With Coronary Artery Disease ("4Steps")

Condition:   Coronary Artery Disease
Interventions:   Behavioral: Peer Mentor;   Behavioral: Transcendental Meditation
Sponsor:   Weill Medical College of Cornell University
Completed

The OPTIMAL Randomized Controlled Trial

Condition:   Left Main Coronary Artery Stenosis
Interventions:   Device: IVUS guided Percutaneous Coronary Intervention;   Device: QCA guided Percutaneous Coronary Intervention
Sponsors:   ECRI bv;   Philips Healthcare;   Boston Scientific Corporation
Not yet recruiting

ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:   Drug: Ticagrelor
Sponsor:   Fondazione per la Ricerca Ospedale Maggiore
Active, not recruiting

Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)

Condition:   Idiopathic Pulmonary Fibrosis
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Identifying Patients in Risk of Post-operative Complications Using PACU Discharge Criteria

Conditions:   Complication,Postoperative;   Post-Op Complication
Intervention:   Other: PACU discharge criteria and continuous monitoring on the ward
Sponsor:   Rigshospitalet, Denmark
Recruiting

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

Condition:   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Apixaban (Eliquis);   Drug: Warfarin
Sponsors:   Bayer;   Janssen, LP
Active, not recruiting

Tonometry(1) and Duplex Ultrasound(2) to Predict CV Events in to be Treated Patients With an AAA

Conditions:   Abdominal Aortic Aneurysm;   Cardiovascular Events
Interventions:   Diagnostic Test: Carotid Artery Reactivity test (CAR test);   Diagnostic Test: Arterial Stiffness
Sponsors:   Rijnstate Hospital;   Radboud University;   Canisius-Wilhelmina Hospital
Not yet recruiting

Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome

Conditions:   Drug Therapy;   Acute Coronary Syndrome
Intervention:  
Sponsor:   Beijing Anzhen Hospital
Not yet recruiting

Effect of Efpeglenatide on Cardiovascular Outcomes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Efpeglenatide (SAR439977);   Drug: Placebo
Sponsor:   Sanofi
Active, not recruiting

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

Conditions:   Venous Thromboembolism;   Multiple Myeloma
Interventions:   Drug: Apixaban;   Drug: Placebo Oral Tablet
Sponsors:   Gregory Piazza;   Bristol-Myers Squibb
Completed

Tailored Antiplatelet Therapy Following PCI

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Stenosis
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor;   Genetic: Retrospective Genotype testing;   Genetic: Prospective Genotype testing;   Other: Smartphone
Sponsors:   Mayo Clinic;   Spartan Bioscience Inc.;   Applied Health Research Centre;   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation

Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients

Conditions:   Frail Elderly;   Coronary Artery Disease
Interventions:   Procedure: Off-pump coronary-artery bypass grafting;   Procedure: On-pump coronary-artery bypass grafting
Sponsors:   University of Sao Paulo General Hospital;   Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo;   Hospital Alberto Urquiza Wanderley;   Hospital das Clínicas Samuel Libânio;   Hospital Samaritano Paulista;   Beneficência Portuguesa de São Paulo;   Hospital Samaritano Campinas;   Instituto Nacional de Cardiologia de Laranjeiras;   Pronto-Socorro Cardiológico Universitário de Pernambuco;   Mount Sinai Hospital, New York
Recruiting

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
Sponsors:   AstraZeneca;   The Cleveland Clinic;   IQVIA RDS Inc.
Active, not recruiting

Evaluating New Radiation Techniques for Cardiovascular Imaging

Condition:   Coronary Disease
Intervention:   Device: The Toshiba Aquilion ONE CT system
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Suspended

Comparative Effectiveness of Empagliflozin in the US

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: DPP-4 inhibitor
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting

Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Aclidinium bromide;   Drug: Other COPD medication
Sponsors:   AstraZeneca;   RTI Health Solutions
Recruiting

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Conditions:   Hypogonadism;   Cardiovascular Diseases
Interventions:   Drug: Testosterone;   Drug: Placebo
Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
Recruiting

Investigation of a Novel Integrated Care Concept (NICC) for Patients Suffering From Chronic Cardiovascular Disease

Conditions:   Heart Failure;   Atrial Fibrillation;   Treatment Resistant Hypertension
Interventions:   Other: Novel integrated care concept (NICC);   Other: Standard care
Sponsors:   University Medical Center Rostock;   Allgemeine Ortskrankenkasse Nordost;   Techniker Krankenkasse;   Philips GmbH Market DACH;   AMEDON GmbH;   Lohfert & Lohfert AG;   Society for Network & Innovation Management of Industry (Germany);   Gemeinsamer Bundesausschuss;   Universitätsmedizin Rostock Versorgungsstrukturen GmbH
Active, not recruiting

Percutaneous Coronary Intervention Registry FRIBOURG

Conditions:   Coronary Artery Disease;   Percutaneous Coronary Intervention
Intervention:   Device: Percutaneous coronary intervention, stents
Sponsor:   University of Freiburg
Recruiting

Registry of Patients With a Bioabsorbable Magnesium Stent Implant MAGMARIS in Usual Clinical Practice

Condition:   Coronary Artery Disease
Intervention:   Device: Magmaris
Sponsor:   Spanish Society of Cardiology
Active, not recruiting

The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.

Conditions:   Coronary Heart Disease;   Anemia;   Bronchial Asthma;   Stroke;   Epilepsy;   Parkinson's Disease;   Heart Rhythm Disorders;   Alzheimer's Disease;   Neuromuscular Diseases;   Diabetes;   Chronic Heart Failure;   Chronic Obstructive Pulmonary Disease;   Chronic Kidney Diseases
Intervention:  
Sponsors:   Russian Federation of Anesthesiologists and Reanimatologists;   Kuban State Medical University
Recruiting

Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy

Condition:   Coronary Artery Disease
Intervention:   Device: SpartanRX
Sponsors:   University of Florida;   National Institutes of Health (NIH);   National Human Genome Research Institute (NHGRI)
Active, not recruiting

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Empagliflozin
Sponsor:   Boehringer Ingelheim
Active, not recruiting

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: XIENCE V EECSS;   Device: Absorb BVS System
Sponsor:   Abbott Medical Devices
Completed

Cost-effectiveness and Safety of the CADScorSystem in Patients With Symptoms Suggestive of Stable Coronary Artery Disease.

Condition:   Angina, Stable
Intervention:   Device: CADScor®System
Sponsors:   Bispebjerg Hospital;   Region Hovedstaden;   Larix A/S;   Acarix;   Kai Hansens Fond;   Kai Houmann Nielsens Fond
Recruiting

Supplemental Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter

Condition:   Coronary Occlusion
Intervention:   Device: NovaCross™ Chronic Total Occlusion micro-catheter
Sponsor:   Nitiloop Ltd.
Completed

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Conditions:   Atrial Fibrillation;   Stroke;   Bleeding
Interventions:   Drug: Antiplatelet-only strategy;   Drug: Oral Anticoagulant plus background antiplatelet therapy
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   Vanderbilt University Medical Center
Not yet recruiting

BiOSS Study (BiOSS LIM C Stent Registry in Bifurcated Lesions)

Condition:   Coronary Artery Disease
Intervention:   Procedure: Coronary angioplasty with stent implantation
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting

Evaluation of Physiological Reactions in Virtual Reality

Conditions:   Pulmonary Disease;   Cardiac Disease
Intervention:   Diagnostic Test: stimulation in virtual reality
Sponsors:   The Opole University of Technology;   IRCCS San Camillo, Venezia, Italy
Not yet recruiting

A Retrospective Study of CT (Computerized Tomography) for Late Window Large Vessel Occlusion (LVO)

Condition:   Stroke, Cardiovascular
Intervention:  
Sponsors:   Boston Medical Center;   Medtronic
Recruiting

Impact of Level and Quality of Immunosuppression on Onset and Pattern of Cardiac Allograft Vasculopathy Evaluated by OCT

Condition:   Transplant; Failure, Heart
Intervention:  
Sponsor:   Klinikum der Universitaet Muenchen
Recruiting

Cryoablation System FIM/CE Mark Study

Condition:   Atrial Fibrillation
Intervention:   Device: The Cryterion Cardiac Cryoablation System
Sponsors:   Boston Scientific Corporation;   Cryterion Medical, Inc.
Recruiting

Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention

Condition:   Cardiovascular Diseases
Intervention:   Behavioral: Intervention
Sponsors:   Umeå University;   Västerbotten County Council, Sweden
Active, not recruiting

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: exemestane
Sponsors:   NCIC Clinical Trials Group;   Grupo Espanol de Investigacion del Cancer de Mama;   UNICANCER
Completed

Milrinone Versus Dobutamine in Critically Ill Patients

Conditions:   Low Cardiac Output Syndrome;   Cardiogenic Shock;   Acute Coronary Syndrome;   Pulmonary Edema
Interventions:   Drug: Milrinone;   Drug: Dobutamine
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting

Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists

Condition:   Pulmonary Disease, Chronic Obstructive
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting

BEST-Registry (vCLI) -Critical Limb Ischemia

Condition:   Critical Limb Ischemia
Intervention:  
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting

DynamX Sirolimus StudySirolimus Eluting Coronary Bioadaptor System

Condition:   Coronary Artery Disease
Intervention:   Device: DynamX Sirolimus-eluting Coronary Bioadaptor System
Sponsor:   Elixir Medical Corporation
Recruiting

Combining Left Atrial Appendage Closure With Cryoballoon Ablation in Chinese Population

Condition:   Atrial Fibrillation
Intervention:   Combination Product: cryoballoon ablation combining with left atrial appendage closure
Sponsor:   Shanghai 10th People's Hospital
Recruiting

Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion

Condition:   Coronary Artery Disease
Intervention:   Biological: Evolocumab
Sponsors:   ECRI bv;   Amgen;   GE Healthcare;   HeartFlow, Inc.
Withdrawn

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid

Condition:   Atherosclerosis
Interventions:   Drug: Rivaroxaban (BAY59-7939, Xarelto);   Drug: Acetylsalicylic acid
Sponsors:   Bayer;   Janssen, LP
Recruiting

Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure

Conditions:   Atrial Fibrillation;   Atrial Appendage;   Hemorrhage
Interventions:   Drug: Rivaroxaban 10 mg qd;   Drug: Rivaroxaban 15 mg qd;   Drug: DAPT
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Action Research Group;   Bayer
Completed

The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial

Condition:   Coronary Artery Disease
Interventions:   Other: Nitrous Oxide;   Other: No Nitrous Oxide
Sponsors:   Bayside Health;   National Health and Medical Research Council, Australia
Completed

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial

Condition:   Ischaemic Stroke
Interventions:   Drug: Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®);   Drug: Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
Sponsor:   University Hospital Inselspital, Berne
Recruiting

COroNary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter Registry (CONFIRM)

Conditions:   Atherosclerosis;   Coronary Artery Disease;   Cardiovascular Disease
Intervention:  
Sponsor:   Weill Medical College of Cornell University
Enrolling by invitation

The Learning Registry

Condition:   Atherosclerotic Cardiovascular Disease
Intervention:  
Sponsors:   Duke University;   Janssen Scientific Affairs, LLC
Enrolling by invitation

A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease

Condition:   Coronary Small Vessel Disease
Interventions:   Device: Cohort A: Dissolve™;   Device: Cohort A: Resolute™ Integrity;   Device: Cohort B: Dissolve™-2.00mm
Sponsors:   DK Medical Technology (Suzhou) Co., Ltd.;   Core Medical (Beijing) Co., Ltd.
Active, not recruiting

A Clinical Trial of IntensiVE Dialysis

Conditions:   Renal Replacement Therapy;   Renal Dialysis;   End Stage Kidney Disease;   End Stage Renal Disease;   Uremia
Intervention:   Procedure: haemodialysis
Sponsors:   The George Institute;   National Health and Medical Research Council, Australia;   Baxter Healthcare Corporation
Completed

A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis

Condition:   Coronary In-stent Restenosis
Interventions:   Device: Dissolve™;   Device: SeQuent®Please
Sponsors:   DK Medical Technology (Suzhou) Co., Ltd.;   Core Medical (Beijing) Co., Ltd.
Active, not recruiting

A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)

Condition:   Contraception
Interventions:   Drug: Nomegestrol acetate (NOMAC);   Drug: Etonogestrel (ENG);   Drug: Ethinyl estradiol (EE);   Drug: Estradiol (E2)
Sponsor:   Merck Sharp & Dohme Corp.
Completed

SPYRAL HTN-ON MED Study

Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
Sponsor:   Medtronic Vascular
Recruiting

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
Sponsor:   Medtronic Vascular
Recruiting

Delirium Reduction by Volatile Anesthesia in Cardiac Surgery

Condition:   Delirium
Interventions:   Drug: Volatile agent;   Drug: Propofol
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Recruiting

Strategies for the Management of Atrial Fibrillation in patiEnts Receiving HemoDialysis

Conditions:   Atrial Fibrillation;   End Stage Renal Failure on Dialysis
Interventions:   Drug: Warfarin;   Drug: Apixaban;   Other: No oral anticoagulation
Sponsors:   St. Michael's Hospital, Toronto;   Canadian Institutes of Health Research (CIHR)
Recruiting

Culotte Versus DK-CRUSH Technique in Non-left Main Coronary Bifurcation Lesions

Conditions:   Coronary Stenosis;   Stent Stenosis
Intervention:   Procedure: Stenting
Sponsor:   University Heart Center Freiburg - Bad Krozingen
Not yet recruiting

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Condition:   Anaemia
Interventions:   Drug: Daprodustat (GSK1278863);   Drug: Placebo;   Drug: Iron therapy
Sponsor:   GlaxoSmithKline
Recruiting

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

Conditions:   Acute Ischemic Stroke;   Transient Ischemic Attack (TIA)
Interventions:   Drug: BMS-986177;   Other: Placebo;   Drug: Clopidogrel;   Drug: Aspirin
Sponsors:   Bristol-Myers Squibb;   Janssen, LP
Recruiting

Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Mitral Regurgitation

Conditions:   Mitral Regurgitation;   Mitral Valve Disease;   Mitral Valve Insufficiency
Intervention:  
Sponsor:   Polares Medical SA
Not yet recruiting

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

Screening for Depression and Anxiety in Patients With Heart Disease

Conditions:   Depression;   Depressive Symptoms;   Depressive Disorder;   Anxiety;   Anxiety Disorders;   Panic Attacks;   Heart Diseases;   Collaboration
Intervention:   Behavioral: Screening and counselling
Sponsors:   Diakonhjemmet Hospital;   Extrastiftelsen;   LHL – The Norwegian Heart and Lung Patient Organization
Completed

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor;   Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
Sponsor:   Boehringer Ingelheim
Active, not recruiting

The SUCCEED Trial of Secondary Stroke Prevention

Conditions:   Stroke;   Secondary Stroke Prevention
Interventions:   Behavioral: Care Management+Community Health Worker;   Behavioral: Usual Care
Sponsors:   University of California, Los Angeles;   University of Southern California;   Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center;   Rancho Los Amigos National Rehabilitation Center;   Olive View-UCLA Education & Research Institute;   National Institute of Neurological Disorders and Stroke (NINDS);   California Community Foundation;   Cedars-Sinai Medical Center
Completed

A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Condition:   Thrombotic Thrombocytopenic Purpura
Interventions:   Drug: Caplacizumab (ALX-0081);   Drug: Plasma exchange (PE);   Drug: Corticosteroid treatment (Methylprednisolone or prednisolone);   Drug: Immunosuppressive treatment (eg, rituximab)
Sponsor:   Sanofi
Recruiting

Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.

Condition:   Cardiogenic Shock
Interventions:   Combination Product: Hydrocortisone + Flucortac;   Other: Placebo
Sponsor:   CMC Ambroise Paré
Recruiting

OCT vs IVUS vs QCA to Guide Moderate-to-severe Calcified Lesion Stent Implantation

Conditions:   Optical Coherence Tomography;   Intravascular Ultrasound;   Angiography
Interventions:   Device: OCT guidance;   Device: IVUS guidance;   Device: QCA
Sponsor:   Shanghai MicroPort Medical (Group) Co., Ltd.
Recruiting

Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)

Condition:   Syncope
Interventions:   Device: Novel ambulatory patch (ZIO® XT Patch);   Biological: BNP and hs-troponin I at 0 and 3 hours post ED attendance
Sponsor:   NHS Lothian
Completed

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Conditions:   Hypertension, Pulmonary;   Ventricular Dysfunction, Left
Interventions:   Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting

A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

Condition:   Coronary Artery Disease
Intervention:   Device: The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Sponsors:   Shanghai Bio-heart Biological Technology Co., Ltd.;   CCRF Inc., Beijing, China
Not yet recruiting

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Completed

STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

Condition:   Intracerebral Haemorrhage
Interventions:   Drug: Tranexamic Acid;   Drug: Normal saline
Sponsors:   Neuroscience Trials Australia;   The Florey Institute of Neuroscience and Mental Health
Recruiting

Belimumab With Rituximab for Primary Membranous Nephropathy

Conditions:   Membranous Nephropathy;   MN
Interventions:   Drug: Belimumab;   Drug: Placebo for Belimumab;   Drug: Rituximab
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN);   GlaxoSmithKline
Not yet recruiting

KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

Conditions:   Glomerular Disease;   Minimal Change Disease;   IgA Nephropathy;   Membranous Nephropathy;   Focal Segmental Glomerulosclerosis;   Lupus Nephritis;   Crescentic Glomerulonephritis
Intervention:   Other: Kidney Biopsy
Sponsors:   Seoul National University Hospital;   Chung-Ang University Hosptial, Chung-Ang University College of Medicine;   KangWon National University Hospital;   Keimyung University Dongsan Medical Center;   SMG-SNU Boramae Medical Center;   Seoul National University Bundang Hospital;   Severance Hospital;   Ministry of Health & Welfare, Korea
Recruiting

The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

Condition:   Coronary Artery Disease
Intervention:   Device: stenting
Sponsor:   Elixir Medical Corporation
Not yet recruiting

Impact of the Reduction in Antihypertensive Treatment on Total Mortality in Frail Subjects With Low Systolic Blood Pressure: Study in Subjects Over 80 Years Living in Nursing Homes

Condition:   Hypertension
Interventions:   Other: STEP DOWN strategy;   Other: Control
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting

The PROtective Ventilation Using Open Lung Approach Or Not Trial

Conditions:   Postoperative Pulmonary Complications;   Respiratory Insufficiency
Intervention:   Procedure: open lung approach
Sponsor:   Sixth Affiliated Hospital, Sun Yat-sen University
Completed

Healing Our Hearts Minds and Bodies: CVD Reduction in Persons With HIV

Conditions:   HIV/AIDS;   Cardiovascular Risk Factors;   Trauma, Psychological
Intervention:   Behavioral: HHMB
Sponsors:   University of California, Los Angeles;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting

"POWER2DM Evaluation Campaign"

Conditions:   Type1 Diabetes Mellitus;   Type2 Diabetes Mellitus;   Diabetes Mellitus;   Health Behavior;   Self Efficacy
Interventions:   Device: POWER2DM system;   Other: Usual care
Sponsors:   Leiden University Medical Center;   Andaluz Health Service
Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Condition:   Influenza A
Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
Sponsor:   Janssen Research & Development, LLC
Recruiting

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Condition:   Influenza A
Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
Sponsor:   Janssen Research & Development, LLC
Recruiting

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes in Non-metastatic, Non-recurrent Lung and Esophageal Cancer Patients

Conditions:   Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8;   Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage I Esophageal Adenocarcinoma AJCC v8;   Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage II Esophageal Adenocarcinoma AJCC v8;   Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Non-Metastatic Lung Carcinoma;   Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage I Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage III Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8;   Stage 0 Lung Cancer AJCC v8;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
Interventions:   Procedure: Biospecimen Collection;   Device: Cardiac Event Monitor;   Other: Chemoradiotherapy;   Radiation: Radiation Therapy
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting

Extended Care in High-Risk Surgical Patient (EXCARE) Pathway in High-risk Surgical Population

Conditions:   Postoperative Complications;   Patient Care Team
Interventions:   Behavioral: Postoperative Monitoring;   Diagnostic Test: High-sensitivity cardiac troponin testing
Sponsor:   Hospital de Clinicas de Porto Alegre
Recruiting

ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement

Condition:   Aortic Stenosis
Interventions:   Device: ACURATE neo2™ Transfemoral TAVR System;   Device: Medtronic CoreValve TAVR System;   Device: Edwards SAPIEN 3 TAVR System
Sponsor:   Boston Scientific Corporation
Recruiting

MitraClip EXPAND G4 Study

Conditions:   Mitral Valve Regurgitation;   Mitral Regurgitation
Intervention:   Device: MitraClip G4 System
Sponsors:   Abbott Medical Devices;   Abbott
Not yet recruiting

Validity and Inter-rater Reliability fo the Vagus Nerve Neurodynamic Test Among Healthy Subjects

Conditions:   Vagus Nerve Diseases;   Diagnoses Disease
Intervention:   Diagnostic Test: Vagus Nerve Neurodynamic test
Sponsors:   University of Turin, Italy;   Politecnico di Milano
Recruiting

Team Clinic: Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents With Type 1 Diabetes

Condition:   Type1 Diabetes
Intervention:   Other: Team Clinic
Sponsors:   Children's Hospital Los Angeles;   University of Colorado Denver School of Medicine Barbara Davis Center;   Cedars-Sinai Medical Center
Not yet recruiting

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed